Since GPC-3 is a transmembrane heparan sulfate proteoglycan also an immunotherapy targeting this protein or affiliated proteins is under investigation in HCC and other diseases in which GPC-3 is overexpressed (Montalbano et al., 2017). The gene discussed is GPC3; the disease is hepatocellular carcinoma.